Stock Track | Kymera Therapeutics Plunges 5.6% Pre-Market Following Q3 Results, Strategic Shift

Stock Track

2024-10-31

Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.

The biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.

In a separate announcement, Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline. The company stated that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. Additionally, Kymera selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1125869736"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125869736\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1125869736?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125869736","market":"hk","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Plunges 5.6% Pre-Market Following Q3 Results, Strategic Shift","media":"Stock Track","content":"<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.</p>\n\n<p>The biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.</p>\n\n<p>In a separate announcement, Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline. The company stated that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. Additionally, Kymera selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Plunges 5.6% Pre-Market Following Q3 Results, Strategic Shift</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Plunges 5.6% Pre-Market Following Q3 Results, Strategic Shift\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-10-31 21:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.</p>\n\n<p>The biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.</p>\n\n<p>In a separate announcement, Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline. The company stated that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. Additionally, Kymera selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1125869736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125869736","pubTimestamp":1730381433,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kymera Therapeutics, Inc.  plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.The biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.In a sepa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"第三季度业绩和战略转变后，Kymera Therapeutics股价盘前暴跌5.6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.\nThe biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.\nIn a separate announcement, Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline. The company stated that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. Additionally, Kymera selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}